Clinical Trials Browser

Head and Neck Neoplasms

NCT06550050 2026-04-16

Clinical and Molecular Features of Oral Premalignancy and Oral Cancer

Recruiting

1,000 enrolled

Head & Neck

Mouth Neoplasms

NCT02819752 2026-04-09

PEACH

Phase 1 Terminated

3 enrolled 12 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05941741 2026-03-18

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Phase 3 Recruiting

380 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07209189 2026-03-09

(NeoScorch HN)

Phase 2 Recruiting

75 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT07447570 2026-03-03

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Phase 2 Recruiting

27 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07432087 2026-02-25

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 3 Not yet recruiting

246 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Phase 1/2 Active not recruiting

194 enrolled

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07335380 2026-01-29

Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma

Phase 1 Not yet recruiting

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03210103 2026-01-28

ORATOR2

Phase NA Active not recruiting

61 enrolled

Head & Neck

Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT06997094 2026-01-26

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

Phase 1 Recruiting

24 enrolled

Head & Neck

Human Papillomavirus-Negative Neck Squamous Cell Carcinoma

Clinical Trials

Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy

Clinical and Molecular Features of Oral Premalignancy and Oral Cancer

PEACH

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

(NeoScorch HN)

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma

ORATOR2

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer